- Home
- CDXS vs OABI Comparison
CDXS vs OABI Comparison
Compare CDXS & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDXS
- OABI
- Stock Information
- Founded
- CDXS 2002
- OABI 2012
- Country
- CDXS United States
- OABI United States
- Employees
- CDXS N/A
- OABI N/A
- Industry
- CDXS Major Chemicals
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- CDXS Industrials
- OABI Health Care
- Exchange
- CDXS Nasdaq
- OABI Nasdaq
- Market Cap
- CDXS 201.3M
- OABI 198.2M
- IPO Year
- CDXS 2010
- OABI N/A
- Fundamental
- Price
- CDXS $2.27
- OABI $1.60
- Analyst Decision
- CDXS Buy
- OABI Strong Buy
- Analyst Count
- CDXS 2
- OABI 3
- Target Price
- CDXS $11.00
- OABI $7.00
- AVG Volume (30 Days)
- CDXS 1.0M
- OABI 1.1M
- Earning Date
- CDXS 08-07-2025
- OABI 08-07-2025
- Dividend Yield
- CDXS N/A
- OABI N/A
- EPS Growth
- CDXS N/A
- OABI N/A
- EPS
- CDXS N/A
- OABI N/A
- Revenue
- CDXS $49,815,000.00
- OABI $26,744,000.00
- Revenue This Year
- CDXS $12.77
- OABI N/A
- Revenue Next Year
- CDXS $22.12
- OABI $45.65
- P/E Ratio
- CDXS N/A
- OABI N/A
- Revenue Growth
- CDXS N/A
- OABI 27.07
- 52 Week Low
- CDXS $1.90
- OABI $1.22
- 52 Week High
- CDXS $6.08
- OABI $4.96
- Technical
- Relative Strength Index (RSI)
- CDXS 48.16
- OABI 54.70
- Support Level
- CDXS $2.20
- OABI $1.35
- Resistance Level
- CDXS $2.51
- OABI $1.81
- Average True Range (ATR)
- CDXS 0.14
- OABI 0.10
- MACD
- CDXS -0.00
- OABI 0.04
- Stochastic Oscillator
- CDXS 42.65
- OABI 71.96
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.